Vaginal Progesterone Versus Cervical Cerclage for Pregnant Women With Short Cervix and History of PTL and/or MTM

NCT ID: NCT02673359

Last Updated: 2023-04-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study to compare vaginal progesterone supplementation to cervical cerclage for prevention of preterm labor in women with short cervical length and history of previous midtrimester miscarriage and/or preterm labor.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Women with singleton pregnancy and history of preterm labor and/or midtrimester miscarriage in a previous pregnancy will be selected for serial assessment of the cervical length by transvaginal sonography (TVS) starting from 16 weeks till 24 weeks of gestation. Eligible participants in our study will be those who have cervical length of 15-25 mm at 16-24 weeks of gestation. At 16-24 weeks gestational age, all women participating in the study will be randomly allocated into two groups; progesterone group and cerclage group. For women in the progesterone group, vaginal progesterone suppositories will be given in a dose of 400 mg/day. For women in the cerclage group, McDonald cervical cerclage will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premature Labour

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Progesterone group

Vaginal progesterone suppositories will be given

Group Type ACTIVE_COMPARATOR

Progesterone

Intervention Type DRUG

Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day

Cerclage group

Cervical cerclage will be performed.

Group Type ACTIVE_COMPARATOR

Cervical cerclage

Intervention Type PROCEDURE

Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Progesterone

Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day

Intervention Type DRUG

Cervical cerclage

Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cyclogest Prontogest Cervical stitch

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women with singleton pregnancy.
* History of preterm labor and/or midtrimester miscarriage in a previous pregnancy.
* Cervical length of 15-25 mm by transvaginal sonography (TVS) at 16-24 weeks of gestation.

Exclusion Criteria

* Age \< 20 or \> 35 years.
* Congenital uterine malformation.
* Multifetal pregnancy.
* Known major fetal structural or chromosomal abnormality.
* Known allergy or contraindication (relative or absolute) to progesterone therapy.
* Presence of contraindication to cervical cerclage.
* Medical conditions complicating pregnancy.
* Vaginal bleeding.
Minimum Eligible Age

20 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mohamed Sayed Abdelhafez

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed Sayed Abdelhafez

Dr

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Waleed El-refaie, Dr

Role: PRINCIPAL_INVESTIGATOR

Port Said University

Mohamed S Abdelhafez, Dr

Role: STUDY_DIRECTOR

Mansoura University

Ahmed M Badawy, Prof

Role: STUDY_CHAIR

Mansoura University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Obstetrics and Gynecology Department in Mansoura University Hospital

Al Mansurah, Dakahlia Governorate, Egypt

Site Status RECRUITING

Private practice settings

Al Mansurah, Dakahlia Governorate, Egypt

Site Status RECRUITING

Obstetrics and Gynecology Department in Port Said University

Port Said, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Waleed El-refaie, Dr

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WR2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cerclage for Twins With Short Cervix
NCT03077633 WITHDRAWN PHASE2/PHASE3
PREGNANT Short Cervix Trial
NCT00615550 COMPLETED PHASE3
The Vaginal Progesterone and Cerclage
NCT02846909 COMPLETED PHASE2
Cerclage for Short Cervix in Twins
NCT02912390 TERMINATED NA
Vaginal Progesterone in Twins With Short Cervix
NCT01812239 WITHDRAWN PHASE2/PHASE3